Chart reviews: Make these changes to prevent payer mistakes
Detailed consent statements are recommended, even for repeated treatments.
Related Articles
Mihir Shah, MD, on racial disparities in depression among patients on ADT
“We noticed that if you were White and had prostate cancer and received androgen deprivation therapy, you were more likely to be diagnosed with depression…
Circulating tumor cell count may serve as a prognostic biomarker in mHSPC
Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.
FDA approves study of Aquablation vs radical prostatectomy in prostate cancer
The WATER IV PCa will assess Aquablation vs radical prostatectomy in patients with grade group 1 to 3 localized prostate cancer.
Dr. Stephen Overholser shares his experience with Aquablation for BPH
“Aquablation is versatile. It can manage a very wide range of prostate sizes and shapes,” says Stephen Overholser, MD.
Cedric Pobel, MD: Key takeaways from PEACE-1 ancillary study
“Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis,” says Cedric Pobel, MD.
Health Canada approves expanded indication of Illuccix in prostate cancer
Illuccix is now indicated for use in the selection of patients with mCRPC for PSMA-targeted radionuclide therapy.
Wayne G. Brisbane, MD, discusses AI-assisted HIFU for prostate cancer
“I think it’s a really nice synergy between the 2 technologies,” says Wayne G. Brisbane, MD.
Dr. Benjamin Pockros on costs of prostate MRI without contrast
“As we expected, the MRIs with contrast were far more expensive,” says Benjamin Pockros, MD, MBA.
PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are…
Dr. Daniel Carson on telehealth vs in-person urology visits
“Patient-reported satisfaction scores were high for both telehealth and inpatient visits for both new and established encounters,” says Daniel Carson, MD, MS.